- Home
- Companies
- asia middle east
- phase 1 clinical
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Phase 1 Clinical Suppliers In Asia Middle East
10 companies found
based inGangnam-gu, SOUTH KOREA
Kangstem Biotech promotes a step-by-step business strategy to optimize its success rate of new global medicine development. Kangstem Biotech will create a world where people can enjoy a healthy and happy life by developing stem cell therapeutic ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
based inSeoul, SOUTH KOREA
CRScube was established in February 2010 by a group of dedicated industry professionals seeking to provide industry-leading eClinical solutions. CRScube is constantly growing with experts across multiple disciplines. Team members use their unique ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral ...
based inYongin-si, SOUTH KOREA
Vivozon is a global innovative drug development company established in 2008. We built an efficacy-based new drug discovery system that is clearly distinct from the existing new drug development paradigm, and discovered the non- narcotic analgesic ...
Opiranserin (VVZ-149) for injection is a first-in-class non-narcotic analgesic under development by Vivozon. As atreatment for postoperative pain used as a first-line therapy in the global market, Opiranserin aims to ultimately replaceopioid ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an ...
based inNanjing, CHINA
Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, ...
FB3001, a new transdermal topical patch, is a musculoskeletal joint pain treatment, currently under clinical development. Through collaboration with ABsize, FB3001's Phase II clinical trial for treating lower back pain has been completed in the ...
based inÉcully, FRANCE
Seqens is an integrated global leader in pharmaceutical solutions and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and custom-made solutions to our customers. Our mission is to bring R&D and industrial ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of ...